Trial Profile
A Randomized Phase III Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin
- Indications Adenocarcinoma; Rectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CinClare
- 08 Jun 2021 Results of long-term outcome, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 29 Oct 2020 Status changed to active, no longer recruiting.
- 29 Oct 2020 Primary endpoint (Pathologic Complete Response) has been met.